MicroPort CardioFlow Medtech (2160) Fundamentals 2026 — Revenue Analysis | SniperIQ
MicroPort CardioFlow Medtech (2160) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$482M, trading at HK$0.98 on the HKSE. This SniperIQ fundamentals page covers MicroPort CardioFlow Medtech's valuation, profitability (net margin -33.3%), revenue (HK$444M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MicroPort CardioFlow Medtech's market cap?
MicroPort CardioFlow Medtech (2160) has a market capitalization of approximately HK$482M, trading at HK$0.98 on the HKSE. Market cap moves with the live share price.
What is MicroPort CardioFlow Medtech's P/E ratio?
MicroPort CardioFlow Medtech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MicroPort CardioFlow Medtech?
MicroPort CardioFlow Medtech runs a net profit margin of -33.3%, a gross margin of 54.7%, and an operating margin of -27.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MicroPort CardioFlow Medtech generate?
MicroPort CardioFlow Medtech reported revenue of HK$444M for fiscal year 2025, with net income of -HK
Does MicroPort CardioFlow Medtech pay a dividend?
MicroPort CardioFlow Medtech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MicroPort CardioFlow Medtech financially healthy?
MicroPort CardioFlow Medtech carries a debt-to-equity ratio of 0.13x and a current ratio of 2.53x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MicroPort CardioFlow Medtech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MicroPort CardioFlow Medtech (2160) the key facts are: market cap HK$482M, revenue HK$444M, 52-week range 0.97-8.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MicroPort CardioFlow Medtech's full fundamentals live
Get MicroPort CardioFlow Medtech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.